Abstract
Recent genomic analyses of metastatic prostate cancer have provided important insight into adaptive changes in androgen receptor (AR) signaling that underpin resistance to androgen deprivation therapies. Novel strategies are required to circumvent these AR-mediated resistance mechanisms and thereby improve prostate cancer survival. In this review, we present a summary of AR structure and function and discuss mechanisms of AR-mediated therapy resistance that represent important areas of focus for the development of new therapies.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Androgen Antagonists / administration & dosage
-
Androstenes / administration & dosage
-
Antineoplastic Agents, Hormonal / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Benzamides
-
Drug Resistance, Neoplasm / genetics
-
Gene Amplification
-
Humans
-
Male
-
Molecular Chaperones
-
Molecular Targeted Therapy
-
Mutation
-
Nitriles
-
Phenylthiohydantoin / administration & dosage
-
Phenylthiohydantoin / analogs & derivatives
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / genetics
-
Prostatic Neoplasms / metabolism
-
Prostatic Neoplasms, Castration-Resistant / drug therapy*
-
Prostatic Neoplasms, Castration-Resistant / genetics
-
Prostatic Neoplasms, Castration-Resistant / metabolism
-
Protein Isoforms
-
Receptors, Androgen / genetics*
-
Receptors, Androgen / metabolism
Substances
-
Androgen Antagonists
-
Androstenes
-
Antineoplastic Agents, Hormonal
-
Benzamides
-
Molecular Chaperones
-
Nitriles
-
Protein Isoforms
-
Receptors, Androgen
-
Phenylthiohydantoin
-
enzalutamide
-
abiraterone